Incidence of de novo malignancies in renal transplant patients after anti-T-lymphocytic therapy.
Kosch
M
M
Könecke
J
J
Hausberg
M
M
Kisters
K
K
D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D011239:Prednisolone / Q000009:adverse effects; D012189:Retrospective Studies
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone